The Israeli trial with cilazapril (Vasocase) for the treatment of hypertension--summary of the care of 413 patients in a community health setting

In a multicenter study in community clinics, 413 patients with mild to moderate essential hypertension were treated with cilazapril (Vasocase), 2.5 mg daily. Patients had either been untreated or had developed side-effects from previous antihypertensive treatment. When response was inadequate the dose was either increased to 5 mg or another antihypertensive medication was added, or both. Treatment significantly reduced systolic and diastolic blood pressures. Pulse rate decreased significantly from the second month of treatment onwards. At the end of the 3rd month of treatment blood pressure was normalized or had decreased by more than 10 mmHg in 91.9% of patients. Physicians' evaluations revealed improvement in 62%; patients' self-evaluations suggested improvement in 61%. Efficacy was equal in all age groups and in both obese and nonobese patients. Antihypertensive response was superior in those with normal renal function. Side-effects were rare and similar to those reported in the literature.

Medienart:

Artikel

Erscheinungsjahr:

2000

Erschienen:

2000

Enthalten in:

Zur Gesamtaufnahme - volume:138

Enthalten in:

Harefuah - 138(2000), 5 vom: 01. März, Seite 345-50, 424

Sprache:

Hebräisch

Beteiligte Personen:

Zimlichman, R [VerfasserIn]

Themen:

19KW7PI29F
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
Cilazapril
Clinical Trial
English Abstract
Journal Article
Multicenter Study

Anmerkungen:

Date Completed 26.07.2000

Date Revised 21.11.2013

published: Print

Citation Status MEDLINE

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM10807434X